Bristol Myers Squibb BMY
NYSE BMY
$63.03 +0.20 (+0.32%)
At close: Sep 18, 2026 · 4:00 PM EDT

Bristol Myers Squibb (BMY) Amortizatization of Intangibles (2009 - 2012)

Bristol Myers Squibb's (BMY) quarterly Amortizatization of Intangibles came in at $102.0 million in Q2 2012, up 7.37% year-over-year from $95.0 million in Q3 2011, and up 0.99% quarter-over-quarter from $101.0 million in Q1 2012.

Analysis

Bristol Myers Squibb (BMY) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends

Bristol Myers Squibb (BMY) has reported Amortizatization of Intangibles for 4 consecutive years, with $102.0 million the latest figure, recorded in Q2 2012.

  • On a quarterly basis, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million in Q2 2012; TTM through Jun 2012 was $388.0 million, a 26.38% increase from a year earlier, with the FY2011 full-year figure at $353.0 million, up 30.26% from the prior year.
  • Amortizatization of Intangibles was $102.0 million for Q2 2012 at Bristol Myers Squibb, up from $101.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $102.0 million in Q2 2012 and troughed at $59.0 million in Q3 2009.
  • A 4-year average of $80.3 million and a median of $75.5 million in 2009 frame the typical range for Amortizatization of Intangibles.
  • Across the five-year window, Amortizatization of Intangibles slipped 6.41% in 2010 and soared 41.79% in 2011, its largest moves.
  • Over 4 years, Amortizatization of Intangibles stood at $78.0 million in 2009, then fell by 6.41% to $73.0 million in 2010, then climbed by 26.03% to $92.0 million in 2011, then increased by 10.87% to $102.0 million in 2012.
  • The last three Amortizatization of Intangibles figures came in at $102.0 million (Q2 2012), $101.0 million (Q1 2012), and $92.0 million (Q4 2011), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn -
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn -
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn -
8 Revolution Medicines 40.91 Bn 40.91 Bn - 4.33 Mn
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2012 102.00 Mn
Mar 31, 2012 101.00 Mn
Dec 31, 2011 92.00 Mn
Sep 30, 2011 93.00 Mn
Jun 30, 2011 95.00 Mn
Mar 31, 2011 73.00 Mn
Dec 31, 2010 73.00 Mn
Sep 30, 2010 66.00 Mn
Jun 30, 2010 67.00 Mn
Mar 31, 2010 65.00 Mn
Dec 31, 2009 78.00 Mn
Sep 30, 2009 59.00 Mn